Three new NASBA-approved live webinar courses on Health Savings Accounts are now available from Roy Ramthun, who led the U.S. Treasury's implementation of HSAs...
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced that, in connection with its previously completed public offering of 15,000,000 shares of Class A common stock of the Company, including 7,698,410 shares being offered by affiliates of American Securities LLC (the “Selling Stockholders”) and 7,301,590 shares being offered by the Company, the underwriters have fully exercised their option to purchase an additional 2,250,000 shares of Class A common stock of the Company, including 1,154,760 shares from the Selling Stockholders and 1,095,240 from the Company at the public offering price of $36.00 per share, less underwriting discounts and commissions. The issuance and sale of the additional shares closed today.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Badger Meter (BMI) To Contact Him Directly To Discuss Their Options
MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the fourth quarter and fiscal year ended on March 31, 2026. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS) Accounting Standards. The results of the Dairy Division (Argentina), which were previously reported under the International Sector, have been classified as discontinued operations, with comparative information presented accordingly, and with its assets and liabilities presented as held for sale.
MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the fourth quarter and fiscal year ended on March 31, 2026. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS) Accounting Standards. The results of the Dairy Division (Argentina), which were previously reported under the International Sector, have been classified as discontinued operations, with comparative information presented accordingly, and with its assets and liabilities presented as held for sale.
This groundbreaking guide uncovers the unseen factors driving authentic leadership and meaningful, personally defined success.CHICAGO, June 4, 2026 /PRNewswire/ -- Executive and leadership coach Nora Bouchard,...
Delivering the Ultimate AAA Gameplay Experience, Display Leader Introduces Three New QD-Mini LED Gaming MonitorsIRVINE, Calif., June 4, 2026 /PRNewswire/ -- TCL®, one of the world's...
GOTHENBURG, Sweden, June 4, 2026 /PRNewswire/ -- Volvo Autonomous Solutions (V.A.S.) and Boliden have completed the autonomous transport project at Boliden's Garpenberg site in...
STOCKHOLM, June 4, 2026 /PRNewswire/ -- Volvo Autonomous Solutions (V.A.S.) and Boliden have completed the autonomous transport project at Boliden's Garpenberg site in Sweden....
VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.02375 per common share for the period of June 1, 2026 to June 30, 2026, which is equal to $0.285 per common share on an annualized basis. The dividend will be paid on June 30, 2026 to shareholders of record as of the close of business on June 15, 2026.
Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.